NAROPIN 10 MG
ROPIVACAINE HYDROCHLORIDE : 10 MG · DIN 02229418 · ASPEN PHARMACARE CANADA INC.
Health Canada status: MARKETED
What is NAROPIN?
NAROPIN 10 MG contains ROPIVACAINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02229418, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for EPIDURAL administration. Health Canada currently lists it as marketed, status dated 11-Jan-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NAROPIN used for?
NAROPIN (ropivacaine hydrochloride) is indicated for: Analgesia Acute pain management in connection with: • Continuous epidural infusion or intermittent bolus administration e.g., postoperative or labour pain; • Field block e.g., infiltration. Anaesthesia Surgical anaesthesia in connection with: • Epidural block for surgery, including Caesarean section; • Major nerve block e.g. brachial plexus block; • Field block e.g. infiltration
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02229418 |
|---|---|
| Brand name | NAROPIN |
| Generic / active ingredient | ROPIVACAINE HYDROCHLORIDE : 10 MG |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | EPIDURAL |
| Schedule | Ethical |
| ATC code | N01BB09 ROPIVACAINE |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Jan-2019 |
| Original market date | 1997-04-14 00:00:00 |
How is it stored and handled?
null
How is it supplied?
100 and 200 mL Polybag (polypropylene infusion bag), packed in a sterile blister pack. 5 mg/mL (20 mL) and 10 mg/mL (10 and 20 mL) Polyamp (polypropylene ampoules suitable for Luer lock and Luer fit syringes), packed in a sterile blister pack.
Is ROPIVACAINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N01BB09 ROPIVACAINE. 6 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NAROPIN | 2 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02229411 |
| NAROPIN | 5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02229415 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 10 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02439409 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 2 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02439379 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02439387 |
| NAROPIN INJ 7.5MG/ML | 7.5 MG | LIQUID | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 02229416 |
| ROPIVACAINE HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02408589 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02347830 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 2 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02403285 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 5 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02347822 |
Who else supplies ROPIVACAINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ROPIVACAINE appears in 49 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.